Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Tata Consultancy Services    TCS   INE467B01029

TATA CONSULTANCY SERVICES

(TCS)
  Report
Delayed Quote. Delayed NSE India Stock Exchange - 01/15 06:14:09 am
3233.35 INR   -0.53%
01/14TATA CONSULTANCY SERVICES : Ex-dividend day for interim dividend
FA
01/13Infosys raises revenue forecast as demand rises
RE
01/12Indian shares hit record high as banks, Airtel gain
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Tata Consultancy Services : TCS Connected Clinical Trials Platform Wins the 2020 Citeline Award

10/06/2020 | 04:52am EST

Tata Consultancy Services' Connected Clinical Trials, Part of the TCS ADD Suite, Received the Recognition for its Technology Excellence in Clinical Research and Drug Development.

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting, and business solutions organization, announced that its TCS Connected Clinical Trials (CCT) platform has won the 2020 Citeline Award in the category 'Best Patient-facing Technology Initiative'. CCT won the award for providing a positive experience to patients participating in clinical trials as well as unlocking superior efficiencies in the overall clinical trials process for sponsors, sites, and niche providers.

The awards, presented by Informa Pharma Intelligence, honor the achievements of those working to advance the quality of human healthcare worldwide by contributing toward bringing new and needed medicines to market. The nominations went through a rigorous review by an independent panel of volunteers from the top echelons of all sectors of the clinical R&D industry, who used their deep knowledge to score entries against the judging criteria.

Part of the TCS ADD platform, CCT is an innovative, cloud-based platform that enables real-time data integration, data-driven analytics and personalized patient support through smart technologies, wearables and mobile apps. It provides end-to-end visibility at patient and site level and lays the foundation for decentralized trials. The platform comprises patient and site engagement, supply management and devices, and connections capabilities.

'With COVID-19 significantly impacting clinical trials, life sciences industries, empowered with technology, are transitioning to a state of decentralized or virtual trials that eliminate the inefficiencies linked with the traditional site-centric approach and embed clinical trials into the daily lives of patients,' said Debashis Ghosh, Business Group Head, Life Sciences and Healthcare, TCS. 'This award validates our focus on providing life sciences organizations with novel technologies and broad cross-stakeholder partnerships to enable decentralized trials, thereby significantly enriching patient engagement, and enhancing test protocol adherence and outcomes.'

'This year's digital event showcased the remarkable innovation, commitment and achievement present across the industry. We are incredibly proud to provide the opportunity to recognize those working in pharma and related industries to drive medical breakthroughs and enhance human health,' said Karen Currie, Executive Director, Citeline. 'While the format of the event is virtual this year, the same high standards of excellence in clinical research and drug development are evident in the achievements of this year's winners including TCS Connected Clinical Trials.'

About TCS ADD platform

TCS ADD is a modern & open drug development platform for life sciences that enables digital ecosystems, simplifies data complexity and provides faster access to new and effective drugs for patients in need. The platform is powered by a cognitive artificial intelligence engine called TCS Decision Fabric, data driven smart analytics and Internet of Things (IoT) that makes clinical trials more agile and safe. TCS ADD leverages the best of cloud architecture and personalized user experience design in compliance with quality guidelines and privacy regulations.

To know more about the TCS ADD Life Sciences platforms, please visit https://www.tcs.com/advanced-drug-development or write to us at ADD.Platforms@tcs.com

About Tata Consultancy Services Ltd. (TCS)

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world's largest businesses in their transformation journeys for over 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent AgileTM delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India's largest multinational business group, TCS has over 443,000 of the world's best-trained consultants in 46 countries. The company generated consolidated revenues of US $22 billion in the fiscal year ended March 31, 2020, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the Dow Jones Sustainability Index (DJSI), MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit us at www.tcs.com

For TCS global news, follow @TCS_News.

TCS ADD Media Contact

Dennis Roman

Email: dennis.roman@tcs.com

Phone: +1 561 865 3339

Vikram Kasbekar

Email: vikram.kasbekar@tcs.com

Phone: +91 2267326147

TCS Media Contacts

Asia Pacific

Email: charlene.lee@tcs.com

Phone: +65 9138 4370

Australia and New Zealand

Email: Kelly.ryan@tcs.com

Phone: +61 422 989 682

Benelux

Email: Joost.galema@tcs.com

Phone: +31 615 903387

Canada

Email: tia.thomas@tcs.com

Phone: +1 647 790 7602

Europe

Email: mattias.afgeijerstam@tcs.com

Phone: +46723989188

India

Email: arushie.sinha@tcs.com

Phone: +91 22 6778 9960

Middle East & Africa

Email: s.hasneen@tcs.com

Phone: +00971567471988

Japan

Email: douglas.foote@tcs.com

Phone: +81 80 2115 0989

Latin America

Email: martin.karich@tcs.com

Phone: +569 6170 9013

Nordics

Email: roland.bagen@tcs.com

Phone: +46703178024

UK

Email: peter.devery@tcs.com

Phone: +44 20 3155 2421

USA

Email: william.thomas@tcs.com

Phone: +1 203 984 3978

Middle East & Africa

Email: s.hasneen@tcs.com

Phone: +00971567471988

Middle East & Africa

Email: s.hasneen@tcs.com

Phone: +00971567471988

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about TATA CONSULTANCY SERVICES
01/14TATA CONSULTANCY SERVICES : Ex-dividend day for interim dividend
FA
01/13Infosys raises revenue forecast as demand rises
RE
01/12Indian shares hit record high as banks, Airtel gain
RE
01/12TATA CONSULTANCY SERVICES : TCS to Buy GE's Stake in Saudi Arabian JV
MT
01/12TATA CONSULTANCY SERVICES : TCS Named a Leader in the IDC MarketScape
AQ
01/12GRAPHIC : Asia's corporate earnings expected to rise 26.4% in 2021, Refinitiv da..
RE
01/11Indian shares close at record highs as IT stocks rally
RE
01/11Indian Stocks See Strong Buying; Tata Consultancy Rises 2%
MT
01/11Nomura Adjusts Tata Consultancy Services' Price Target to 3,070 Indian Rupees..
MT
01/11Indian shares hit record high as TCS earnings lift IT stocks
RE
More news
Financials
Sales 2021 1 644 B 22 470 M 22 470 M
Net income 2021 329 B 4 501 M 4 501 M
Net cash 2021 264 B 3 614 M 3 614 M
P/E ratio 2021 36,7x
Yield 2021 1,46%
Capitalization 11 960 B 164 B 163 B
EV / Sales 2021 7,11x
EV / Sales 2022 6,22x
Nbr of Employees 469 261
Free-Float 26,9%
Chart TATA CONSULTANCY SERVICES
Duration : Period :
Tata Consultancy Services Technical Analysis Chart | TCS | INE467B01029 | MarketScreener
Technical analysis trends TATA CONSULTANCY SERVICES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 40
Average target price 3 259,03 INR
Last Close Price 3 233,35 INR
Spread / Highest target 29,2%
Spread / Average Target 0,79%
Spread / Lowest Target -41,9%
EPS Revisions
Managers and Directors
NameTitle
Rajesh Gopinathan CEO, MD & Non-Independent Executive Director
Natarajan Chandrasekaran Non-Executive Chairman
N. Ganapathy Subramaniam COO & Non-Independent Executive Director
V. Ramakrishnan Chief Financial Officer
K. Ananth Krishnan Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
TATA CONSULTANCY SERVICES12.95%163 507
ACCENTURE PLC-2.89%160 874
INTERNATIONAL BUSINESS MACHINES CORPORATION1.99%114 403
INFOSYS LIMITED7.10%78 019
AUTOMATIC DATA PROCESSING, INC.-8.11%69 091
VMWARE, INC.-3.89%56 590